BioXcel Therapeutics, Inc.

BTAI · NASDAQ
Analyze with AI
$1.90+$0.025 (+1.34%)
At close:Dec 16, 2025, 7:11 PM UTC
$1.90+$0.00 (+0%)
After hours:Dec 16, 2025, 7:10 PM UTC
P/E TTM-0.29
P/B TTM-0.14
P/S TTM47.75
Dividend Yield0%
EPS-$9.29
Beta0.209
Valuation
PEG Ratio-0.05
FCF Yield-134.56%
EV / EBITDA-3.38
More On Valuation »
Quality
ROIC-1,410.73%
Gross Margin-151.61%
Cash Conv. Ratio1.09
More On Quality »
Growth
Revenue 3Y CAGR82.14%
FCF Growth53.54%
More On Growth »
Safety
Net Debt / EBITDA-2.33
Interest Coverage-3.42
More On Safety »
Efficiency
Inventory Turnover4.34
Cash Conv. Cycle-2,680.70
More On Efficiency »

BioXcel Therapeutics, Inc. (BTAI) stock FAQs

Quick answers sourced from live Financial Modeling Prep fundamentals and AlphaPilot portfolio guidance.

What is BioXcel Therapeutics, Inc. (BTAI) stock price today?

As of Dec 16, 2025, 7:11 PM UTC, BioXcel Therapeutics, Inc. (BTAI) stock is trading at $1.90. The stock price is quoted in USD and refreshes in real-time throughout the trading day. AlphaPilot provides live market data powered by Financial Modeling Prep's institutional-grade API, ensuring you get accurate and up-to-date BTAI stock quotes for informed trading decisions.

What is BioXcel Therapeutics, Inc.'s market capitalization?

BioXcel Therapeutics, Inc. (BTAI) has a market capitalization of approximately $41.4M. Market cap is calculated by multiplying the current share price by the total number of outstanding shares. This valuation metric helps investors compare BioXcel Therapeutics, Inc.'s size relative to other companies in the USD market. The market cap figure updates automatically as the BTAI stock price changes.

What is the 52-week range for BioXcel Therapeutics, Inc. stock?

BioXcel Therapeutics, Inc. (BTAI) stock has traded in a 52-week range of $1.17 — $9.26. The 52-week range shows the highest and lowest prices at which BTAI traded over the past year, helping investors assess price volatility and identify potential support and resistance levels. Comparing the current BioXcel Therapeutics, Inc. stock price to this range provides context for recent price action.

How much trading volume does BioXcel Therapeutics, Inc. stock have?

BioXcel Therapeutics, Inc. (BTAI) stock recently traded approximately 304.9K shares. Trading volume indicates market liquidity and investor interest in BTAI. Higher volume typically suggests active participation and can signal important price movements or news catalysts affecting BioXcel Therapeutics, Inc. stock.

Does BioXcel Therapeutics, Inc. pay dividends to shareholders?

Yes, BioXcel Therapeutics, Inc. (BTAI) currently offers a dividend yield of approximately 0%. Dividend yield is calculated by dividing the company's annual dividend payments by the current stock price, expressed as a percentage. This metric helps income-focused investors evaluate BioXcel Therapeutics, Inc. stock's potential for generating passive income. Dividend data reflects the trailing twelve months (TTM) of distributions.

What is BioXcel Therapeutics, Inc.'s intraday price range?

Today, BioXcel Therapeutics, Inc. (BTAI) stock has traded in a range of $1.86 — $1.95. The intraday range represents the lowest and highest prices reached during the current trading session. Monitoring BTAI's intraday volatility helps traders identify entry and exit points, while comparing it to the 52-week range provides perspective on short-term versus long-term price movements.

Where does AlphaPilot get BioXcel Therapeutics, Inc. stock data?

AlphaPilot sources real-time BTAI stock quotes, fundamental financial data, and historical price charts for BioXcel Therapeutics, Inc. from Financial Modeling Prep's institutional-grade API. This enterprise data feed provides live market prices during trading hours, along with comprehensive fundamentals that update after each earnings release, SEC filing, or corporate action. The BioXcel Therapeutics, Inc. stock summary page combines intraday price movements with key metrics like P/E ratio, market cap, dividend yield, and balance sheet data to give investors a complete view of BTAI stock performance.